<DOC>
	<DOCNO>NCT00618241</DOCNO>
	<brief_summary>The purpose study determine whether interaction raltegravir lamotrigine take place study safety combination raltegravir/lamotrigine use HIV patient .</brief_summary>
	<brief_title>Pharmacokinetic Study Raltegravir Lamotrigine</brief_title>
	<detailed_description>Lamotrigine anticonvulsive drug use treatment HIV-associated neuropathic pain treatment epilepsy HIV-infected individual . Lamotrigine metabolize via glucuronidation . Raltegravir newly develop integrase inhibitor also metabolize via glucuronidation . Since agent metabolize via glucuronidation , possibility competition glucuronidation , lead drug-drug interaction raltegravir lamotrigine . This primary objective study determine effect raltegravir pharmacokinetics single dose lamotrigine ( intrasubject comparison ) . A secondary objective determine effect single dose lamotrigine pharmacokinetics raltegravir compare historical control . Another secondary objective evaluate safety combine use single dose lamotrigine raltegravir .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Between 18 55 year age Subject smoke 10 cigarette , 2 cigar 2 pipe per day Subject Quetelet Index 18 30 kg/m2 Subject able willing sign inform consent Subject good ageappropriate health condition Subject normal blood pressure pulse rate History sensitivity/idiosyncrasy medicinal product excipients Positive HIV test Positive hepatitis B C test Therapy drug ( 2 week precede dose ) except paracetamol Relevant history presence pulmonary disorder , cardiovascular History current abuse drug , alcohol solvent Inability understand nature extent trial procedure Participation drug trial within 60 day prior first dose Donation blood within 60 day prior first dose Febrile illness within 3 day first dose</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>interaction</keyword>
	<keyword>neuropathic pain</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>